What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar-- INFLIXIMAB-DYYB or others--makes good pharmacoeconomic and clinical sense?

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar-- INFLIXIMAB-DYYB or others--makes good pharmacoeconomic and clinical sense?

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar— INFLIXIMAB-DYYB or others—makes good pharmacoeconomic and clinical sense, as opposed to using the reference brand product, infliximab? How do we advocate for the patient?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Leonard Calabrese, DO

Leonard Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute